Antithrombotic status and intracerebral hemorrhage in the setting of extracorporeal membrane oxygenation

BACKGROUNDNontraumatic intracerebral hemorrhage (ICH) is among the most devastating complications of extracorporeal membrane oxygenation (ECMO), and its management confronts an unresolved tension between hemorrhage extension and the thrombotic demands of the circuit.Antithrombotic status at the time of hemorrhage reflects underlying indication and illness severity, and the timing of ICH relative to cannulation may modify its prognostic significance.Large multicenter data examining outcomes by both antithrombotic status and hemorrhage timing are limited. AIMTo evaluate 30-day outcomes among patients with nontraumatic ICH in the setting of ECMO, stratified by recorded antithrombotic status at the index date and by the timing of hemorrhage relative to ECMO initiation. METHODSThis was a retrospective multicenter cohort study using the TriNetX Research Network Database (2016)(2017)(2018)(2019)(2020)(2021)(2022)(2023)(2024)(2025).Adults ≥ 18 years with ICH in the 30 days before or during ECMO were included in the analysis.Patients were stratified by recorded antithrombotic medication status at the index date: systemic anticoagulation (AC), dual therapy (DT; AC plus antiplatelet therapy), or no antithrombotic therapy (NT).Post-ICH antithrombotic management was not captured; discontinuation after ICH was presumed per standard practice but could not be verified.Primary outcome was 30-day mortality.Secondary outcomes were 30-day cardiac arrest and ischemic stroke; exploratory outcomes included blood transfusion and repeat ICH coding.Outcomes were evaluated across four ECMO windows: Pre-ECMO (-30 to 0 days), early (0-3 days), intermediate (3-14 days), and late (14-30 days).Hazard ratio (HR) was calculated for each predetermined outcome.All HRs in the setting of extracorporeal membrane oxygenation.

Authors

Institutions

Publication Details

Journal
World Journal of Critical Care Medicine
Published
2026-11-12
DOI
https://doi.org/10.5492/wjccm.126670
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antithrombotic status and intracerebral hemorrhage in the setting of extracorporeal membrane oxygenation

Abbasali Badami, Andrea Loggini, Denise Battaglini, Amir Mahdi Ghafarian et al.
World Journal of Critical Care Medicine
Mechanical Circulatory Support Devices
article

Antithrombotic status and intracerebral hemorrhage in the setting of extracorporeal membrane oxygenation

Abbasali Badami, Andrea Loggini, Denise Battaglini, Amir Mahdi Ghafarian, Khaled Saleh, Adnan I Qureshi, Muazz Wajahath, Faddi Saleh Velez, Mohammad Ghafarian, Zoya Syed
article en

Abstract

BACKGROUNDNontraumatic intracerebral hemorrhage (ICH) is among the most devastating complications of extracorporeal membrane oxygenation (ECMO), and its management confronts an unresolved tension between hemorrhage extension and the thrombotic demands of the circuit.Antithrombotic status at the time of hemorrhage reflects underlying indication and illness severity, and the timing of ICH relative to cannulation may modify its prognostic significance.Large multicenter data examining outcomes by both antithrombotic status and hemorrhage timing are limited. AIMTo evaluate 30-day outcomes among patients with nontraumatic ICH in the setting of ECMO, stratified by recorded antithrombotic status at the index date and by the timing of hemorrhage relative to ECMO initiation. METHODSThis was a retrospective multicenter cohort study using the TriNetX Research Network Database (2016)(2017)(2018)(2019)(2020)(2021)(2022)(2023)(2024)(2025).Adults ≥ 18 years with ICH in the 30 days before or during ECMO were included in the analysis.Patients were stratified by recorded antithrombotic medication status at the index date: systemic anticoagulation (AC), dual therapy (DT; AC plus antiplatelet therapy), or no antithrombotic therapy (NT).Post-ICH antithrombotic management was not captured; discontinuation after ICH was presumed per standard practice but could not be verified.Primary outcome was 30-day mortality.Secondary outcomes were 30-day cardiac arrest and ischemic stroke; exploratory outcomes included blood transfusion and repeat ICH coding.Outcomes were evaluated across four ECMO windows: Pre-ECMO (-30 to 0 days), early (0-3 days), intermediate (3-14 days), and late (14-30 days).Hazard ratio (HR) was calculated for each predetermined outcome.All HRs in the setting of extracorporeal membrane oxygenation.

World Journal of Critical Care Medicine
University of Toronto (CA), University of Medicine and Health Sciences (KN), Memorial Hospital of Carbondale (US), Southern Illinois Healthcare (US), OU Health (US), University of Oklahoma Health Sciences Center (US)
Good health and well-being
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon